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An experimental study of use of absorbable plate in combination with self-setting 




Purpose: The purpose of this study was to histologically and immuno-histochemically 
evaluate bone formation using both of self-setting α-tricalcium phosphate (α-TCP; 
BIOPEX®) and absorbable plate (Super FIXSORB®-MX) in rabbit cranium bone.  
Study design: Adult male Japanese white rabbits (n=16, 12-16 weeks, 2.5-3.0 kg) were 
used. The surgical defects were made in the nasal bone of a rabbit and BIOPEX® was 
implanted in the left side and no material in the right side. Two-hall-absorbable plate 
and two screws (Super FIXSORB®-MX) were fixed across the defect in each side. The 
rabbits were sacrificed at1, 4, 12 and 24 weeks postoperatively, and formalin-fixed 
specimens were embedded in acrylic resin. The specimens were stained with 
hematoxylin and eosin. For immune-histochemical analysis, the specimens were treated 
with bone morphogenetic protein-2 (BMP-2) antibodies. Finally, these were evaluated 
microscopically. 
Results: New bone formation was observed in the region of absorbable plate and nasal 
membrane after more than 4 weeks. The area of BIOPEX®＋new bone was significantly 
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larger than that of control side after 1, 4 and 12 weeks (P<0.05). The number of BMP-2 
stained cell in experimental side was significantly larger than that in control side after 4 
and 12 weeks (P<0.05). 
Conclusion: This study suggested that the use of absorbable plate (Super 
FIXSORB®-MX) in combination with BIOPEX® were useful and both of Super 
FIXSORB®-MX and BIOPEX® could provide adequate bone regeneration. 
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Late, absorbable plate systems are being used increasingly in oral and maxillofacial 
surgery.1,2 The biodegradable devices have major advantages over conventional metallic 
implants. There is no need for a second operation to remove the implant. There is less 
risk of weakening of the fixed bone because of stress shielding and there is no risk of 
metallic corrosion. However, several problems remain, including mechanical 
weakness,3,4 late foreign body reactions, osteolytic change, and micro-movement of 
fixed bone caused by a low initial stability.5,6,7 
Recently, resorbable bone fixation devices (Super-FIXSORBⓇ-MX. Takiron Co. Ltd, 
Osaka) have been developed for use in orthopedic or cranio-facial, oral and 
maxillofacial or plastic and reconstructive surgeries.8,9,10 These devices are made from 
composites of uncalcined and unsintered hydroxyapatite (u-HA) particles and 
poly-L-lacted (PLLA), and they are produced by a forging process, which is a unique 
compression molding, and machining treatment. They have a modulus of elasticity close 
to that of natural cortical bone, and they can retain a high strength during the period 
required for bone healing. They can also show optimal degradation and resorption 
behavior, osteoconductivity, and bone bonding capability. 
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 On the other hand, Monma et al.11 have originally developed a self-setting 
cement-type calcium phosphate material consisting of α-TCP, dicalcium phosphate 
dibasic (DCPD) and tetracalcium phosphate monoxide (TeCP). According to their 
extensive studies, this cement-type material could be refined, demonstrating better 
biocompatibility and direct integration to bone without any participation of peripheral 
soft tissue.12-16 As it is free of the infiltration with time of residual monomers of 
methacrylate resin, which has long been used for orthopedic treatment, this self-setting 
cement came to be rapidly highlighted for clinical use in Japan. 
In orthognathic surgery, use of bone graft was sometimes needed in the contact area 
between segments in sagittal split ramus osteootomy or Le Fort I osteotomy.17,18 Use of 
a plate and screw system only was enough to fix the segments and maintain the stability, 
according to previous reports.1,2 However, the  absorbable plate system was used in 
cases where the space between the bony segments was wide, and whether proper 
rigidity and stability can be achieved was also considered.  Therefore, the combined 
use of segmental fixation with absorbable plate system and filling in the space between 
the segments were assumed to be clinically necessary. 
The purpose of this study was to histologically and immuno-histochemically evaluate 
bone formation using both self-setting α-tricalcium phosphate (α-TCP; BIOPEX®) and 
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absorbable plate (Super FIXSORB®-MX) in rabbit cranium bone. 
 
Materials and Methods 
 
The experimental protocol was approved by the Institutional Committee for 
Animal Care, Kanazawa University. Sixteen male Japanese white rabbits (12-16 weeks, 
2.5-3.0 kg) were used in this study.  
 
Surgical procedure 
 The entire procedure was performed under sterile conditions. First, the animals 
were anesthetized with sodium pentobarbital (25 mg/kg) by injection into the lateral ear 
vein. After the hair in the nasal region was shaved, 1.8 ml of 2% lidocaine containing 
1:80,000 epinephrine was administered to the surgical site. Both the nasal bone and 
nasoincisinal suture line were exposed via a perpendicular incision. With the use of a 
fissure bur, four nasal bone windows were outlined. A surgical defect (3×20 mm) was 
made with a fissure bur using continuous saline irrigation. The interval between screw 
halls of the uHA/PLLA plate was approximately 4 mm, so that the size of more than 3mm 
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could be choosen. The surgical defect was divided two areas; the right was the control 
side and the left was the experimental side (Fig 1).  
 
Implant materials and fixation plate  
 The implant materials were α-TCP/DCPD/TeCP cement (BIOPEXⓇ, 
Mitsubishi Materials, Yokose, Chichibu, Japan).  The cement powder consisting of 
α-TCP(75% wt), DCPD (5% wt) and TeCP (20% wt) were mixed with an aqueous 
solution containing 12 % sodium succinate and 5 % sodium chondroitin sulfate to 
prepare the cement paste. A power/liquid ratio of 3.0 was chosen for ease of mixing and 
sufficient strength as a filling material, according to the results of Kurashina et al.12 The 
cement paste was implanted in the defect on the left side area (3×10 mm). No material 
was implanted into the right side. On each side, Super-FIXSORBⓇ-MX plate (straight, 
2 halls) and two screws (2×5 mm) were fixed across the surgical defect (Fig.1). 
 
Histological examination 
The rabbits were sacrificed at 1, 4, 12 and 24 weeks postoperatively and the 
specimens were collected for hematoxylin and eosin staining and also for 
immunno-histochemical analysis. After fixation with 10% phosphate-buffered formalin, 
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the specimens with the titanium mesh were dehydrated in ethanol and technovit 
7200VCL (Kultzer and Co., GmbH, Wehreim, Germany) and then embedded in acrylic 
resin. The embedded blocks were trimmed by a cutter and ground by abrasive paper. 
Thereafter, the sections were further ground to a final thickness of about 10 μm. Finally, 
the specimens were stained with hematoxylin and eosin and examined under the 
microscope. The observation area was located between two screws and between 
absorbable plates and the nasal membrane (Fig.2). The bone or BIOPEXⓇ area ratio 
was measured with image software (Scion image, Scion corporation ML, USA).  
The prepared sections were deacrylated in 2-methoxyethyl acetate, inhibited by 
endogenous peroxidase with 0.3% hydrogen peroxide and blocked in 10% normal 
serum prior to staining. For immunostaining, commercially available monoclonal 
anti-BMP-2 antibodies (Dako North America, Inc, CA, USA) were used. Sections were 
incubated overnight with these primary antibodies at 4ºC in a humidified chamber. A 
biotinylated goat anti-mouse IgG antibody (Wako Junyaku Inc., Osaka, Japan) was used 
as the secondary antibody. The Vectastain-Elite ABC kit detection system, DAB 
revelation kit and DAB enhancing solution (Wako Junyaku Inc., Osaka, Japan) were 
used to complete the immunostaining. Finally, a light Meyer’s hematoxylin counter 
stain was applied. The sections were then dehydrated in alcohol and mounted for light 
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microscopy to count the number of positively stained active cells in the regeneration site. 
The observation area was located near the nasal membrane in the middle area between 
two screws (Fig.2). The number of BMP-2 stained cells per voluntary 1000 cells in this 
area was counted by hand using high magnification photomicrograph (×100). 
 
Statistical Analysis  
Data of all the implanted materials were statistically analyzed with Stat View 4.5 
(ABACUS Concepts, Inc., Berkeley, CA, USA). Differences between groups were 
analyzed by non-paired comparison using Scheffe’s F test. Time-dependent changes 
were examined by analysis of variance (ANOVA). Differences were considered 




Healing progressed uneventfully in all animals and no postoperative 
complications were noted during the 24-week observation period. After resting for 3-6 




Absorbable plate region 
 
   After 1 week, on the experimental side, fibrous tissue or cell component including 
osteoblast was not found between absorbable plate and BIOPEX®, because there was no 
space between the plate and BIOPEX® paste. On the control side, fibrous tissue or cell 
components were not observed and the surgical defect area was empty (Figs.3 and 4). 
  After 4 weeks, fibrous tissue or cell components including osteoblasts were 
recognized on both the experimental and control sides. In the experimental group, 
fibrous tissue was located in the gap between the absorbable plate and BIOPEX®. 
However, resorption of BIOPEX® by osteoclasts was not seen in the experimental side. 
Absorbable plate resorption was not seen in both sides (Fig. 5). 
  After 12 weeks, fibrous tissue decreased and new bone formation was found in both 
sides. On the experimental side, resorption of surrounding BIOPEX® derived from 
osteoclasts was observed. Although absorbable plate resorption was not seen, new bone 
formation was observed under the plate in both sides (Fig. 6). 
 After 24 weeks, in the control side, new bone formation increased gradually. However, 
similar findings were seen up to 12 weeks in the experimental side (Fig. 7).  
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Nasal membrane region 
 
 After 1 week, the nasal membrane was still not significantly regenerated in both sides. 
However, after 4, 12 and 24 weeks, the nasal membrane repaired in both sides and 
similar findings were observed in both sides. After 12 weeks, resorption of BIOPEX® in 
nasal membrane region showed a tendency to be less than that in the absorbable plate 




With regard to the bone area, the subjects were divided into 4 groups as follows and 
statistical calculations performed.  
Area A: Bone area in the experimental side,  
Area B: Bone area in the control side,  
Area C: BIOPEX area in experimental side  
Area D (Area A+C): Bone area + BIOPEX® area. 
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 The time-course change was significant, however there was not significant difference 
between the groups by repeated measure ANOVA (between subjects; F=373.634, df=3, 
P=0.0048; within subjects; F=69.152, df=9, P=0.4997). Although there was no 
significant difference between area A and B in all the periods, bone area in both groups 
increased gradually. In contrast, area C decreased gradually. Although area C was 
significantly larger than area B after 1 week (P=0.082), there was no significant 
difference between area C and B after 4, 12 and 24 weeks. Area D was significantly 
larger than area A after 1 (P=0.0009), 4 (P=0.0030) and 12 weeks (P=0.0375), however, 
there was no significant differences between areas D and A after 24 weeks. Area D was 
significantly larger than area B after 1 (P=0.0003), 4 (P=0.008) and 12 weeks 
(P=0.0156), however, there was no significant differences between areas D and B after 
24 weeks. Area D was significantly larger than area C after 12 weeks (P=0.0482), 
however, there was no significant differences between areas D and C after 1, 4 and 24 
weeks (Fig. 8). 
 
Number of BMP-2 stained cells 
 
Fibrous tissue and cell components including osteoblasts did not exist in the 
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observation region so that the number of BMP-2 stained cells could not be counted after 
1 week. The time-course change was not significant, and there was no significant 
difference between the groups by repeated measure ANOVA. However, the number of 
BMP-2 stained cells in the experimental side was significantly larger than that in the 




  Orthognathic surgery is frequently performed all over the world, and Le Fort I 
osteotomy and sagittal split ramus osteotomy are well-known standard surgical 
procedures. 
    In Le Fort I osteotomy, incomplete ossification of osteosynthesis is one of the 
major problems.17 If the size of the defect between the advanced inferior maxillary 
segment and the superior segment exceeds 3mm at the levels of the piriform rim and 
zygomaticomaxillary junction following Le Fort I osteotomy, use of a bone graft may 
be required for stabilization. Furthermore, bone recovery would be inadequate if there is 
a defect of more than 3 mm between the segments along the line of osteosynthesis. The 
line of osteosynthesis would involve a fibrous tissue rather than osseous tissue. In this 
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case, resistance to relapse would be via this fibrous tissue and the initial plate and screw 
rather than a robust osseous tissue.17,18 However, absorbable plate systems are being 
used increasingly in oral and maxillofacial surgeries. In our previous report, there was no 
difference in the stability following Le Fort I osteotomy without bone graft between a 
titanium plate group and an absorbable plate group in most frontal and lateral 
cephalometric measurements. However, a significant difference in the A point in the 
lateral cephalometric measurements was found between the two groups.1 This suggested 
that the difference between titanium and the absorbable plate could affect the stability 
following Le Fort I osteotomy.  
Our previous study showed that the gap between the proximal and distal 
segments could fill up with new bone after SSRO with titanium or absorbable plates, even 
if there were few bony contacts between the segments. However, a concave outline was 
observed in some cases in the study, although the square of ramus increased 
significantly.19 If healing of the periosteal membrane at the incision area is complete, it 
can prevent invasion of mucosal endothelial cells into the gap between segments. 
Ideally, when the absorbable plate is used in Le Fort I osteotomy or SSRO, 
significant strength by bony healing between segments is necessary to maintain skeletal 
stability after a decrease in strength in the absorbable plate and screw. 
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   uHA/PLLA plate system (Super-FIXSORBⓇ-MX) which have completed clinical 
tests in orthopedic, oral and maxillofacial surgeries exhibit total resorbability and 
osteological bioactivity such as the ability to directly bond to bone and 
osteoconductivity20 as well as good biocompatibility and high stiffness retainable for a 
long period of time to achieve bone union.21 Shikinami et al. documented the complete 
process of bioresorption and bone replacement of rods made of forged composites of 
unsintered hydroxyapatite particles/poly L-lactide (F-u-HA/PLLA) implanted in the 
femoral medullary cavities of rabbits.10 From the results, it was found that 
morphological changes during biodegradation and bone replacement in the proximal 
medullary cavity up to 4.5 years, and molecular weight and the bending strength had 
decreased to 50 KDa and 200 MPa after 6 months. Therefore, if the strength of the 
absorbable plate decreases and the bony healing between segments is not complete at 
least 6 months after osteotomy, the skeletal stability can not sustain for a long time. 
     To achieve osseous healing, a grafted material needs to serve as a scaffold for 
the migration, attachment, and subsequent differentiation of osteoprogenitor cells from 
the recipient bed.22,23 Various types of biocompatible graft materials have been 
developed in consideration of bone regeneration and augumentation as well as further 
procedures such as dental implantation24-26.  Autogenous bone graft has drawbacks 
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such as the requirement of a second operation, which is sometimes accompanied by 
broad invasion, and a restricted source of materials. Alloplastic materials composed of 
inorganic substances such as tricalcium phosphate (TCP) or hydroxyapatite show 
biocompatibility and osteoconductivity,27,28 a major reasons why this type of material 
has been widely employed for hard tissue repair.29-31 α-TCP is predominant during bone 
resorption in the early stage of bone healing;32-35 this may lead to technically difficulties 
in both the filling of particles to fit the bone defects and their delivery to form the 
desired shape.36-40 However, cement type calcium phosphate material in paste form 
processes self-setting property in situ, thereby solving these technical problems.41-44 The 
characteristic properties of the self setting materials work to prevent  intervention for 
undesirable connective tissues or dispersion of the calcium phosphate particles in to the 
surrounding tissue. 
 Bone morphogenetic proteins (BMPs) are active bone-inducing factors that 
act on immature mesenchymal cells, including osteoblasts, resulting in osteogenesis.  
So far, several types of BMPs have been isolated using molecular cloning, and 
recombinant BMP molecules have been synthesized.45 Recombinant human BMP-2 
(rhBMP-2) is a molecule that powerfully induces bone generation in vivo.46  Bone 
formation depends mainly on the number of osteoblastic cells rather than the activity of 
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the osteoblasts.47  The recruitment of osteoblastic cells plays a crucial role in 
osteogenesis. Within subperiosteal implantation sites, BMP induces new bone formation 
in heterotrophic, intramuscular and orthotropic sites in vivo.48  It is thought that BMP 
induces the differentiation of pre-vascular mesenchymal connective tissue cells into 
bone and cartilage.  Therefore, an immuno-histochemical study using BMP antibody 
was very adequate to examine the possibility of bone-induced effects, but there have 
been no reports on the expression of BMP induced by α-TCP.  In our previous study of 
onlay graft using rabbit mandible,49 in the immuno-histochemical examination after 
treatment with BMP-2 antibody, when the autologous group was compared with the 
control and β-TCP groups, the cell numbers increased significantly , and there was no 
significant difference between control and β-TCP in terms of cell number for 2, 4 and 8 
weeks. This suggested that bone inductive activity of β-TCP could be low. On the 
other hand, Yuan et al.50 founded that porous β-TCP ceramic could induce bone 
formation in soft tissue in dogs, but porous α-TCP ceramic could not. They concluded 
that no bone formation in α-TCP might have resulted from its higher resorbability or 
more accurately, due to its rapid dissolution.  The rapid dissolution of α-TCP also 
affected its cell-mediated resorption. Self-setting of α-TCP (BIOPEX®) in this study 
was different from that of porous α-TCP so that they cannot be readily compared. 
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 In this study, fibrous tissue and cell components including osteoblasts were 
absent in the observation region, therefore, the number of BMP-2 stained cells could not 
counted after 1week. This suggested that tight contact could be obtained between the 
absorbable plate and BIOPEX® . The number of BMP-2 stained cells in the 
experimental side was significantly larger than that in the control side after 4 and 12 
weeks. This suggested that osteoblast cells were localized onto the BIOPEX® and the 
absorbable plate. The deposited bone matrices on these materials implied a coupling 
between osteoclasts and osteoblasts. Resorption of the BIOPEX® was observed after 12 
weeks at the region of the absorbable plate, but that was after 24 weeks at the region of 
the nasal membrane. This suggested that the resorption of the BIOPEX® was 
comparatively slow, but different in the region of the implant. In the study of Hao et 
al.51 using rabbit femoral cortical bone, a range of osteoclasts accumulated on the 
surface of the BIOPEX® , whilst many osteoblasts were localized on the surface 
opposing the  BIOPEX®  from days 5 to 10. However, remnants of the BIOPEX® 
particles were present in the new born with a profile of compact bone on days 30 and 40. 
The BIOPEX® was so hard that the osteoclasts could not resorb rapidly.  
Although, the number of BMP-2 stained cells in the experimental side was 
significantly larger than that in the control side, there was no difference in the new bone 
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formation area between the control and experimental sides. For the reason, it was 
suggested that area of the BIOPEX® occupied a large area of the surgical defects and 
thus the bone formation area became narrow. However, the total area of the new bone 
and BIOPEX® was constantly larger than the new bone of the control sides until 12 
weeks. This suggested that strength in the space of the surgical defects could be 
supported by not only the absorbable plate, but also implant of BIOPEX® and sequential 
new bone formation. However, after 24 weeks, there were no significant difference in 
the bone area among all areas. This might be because new bone formation increased in 
the control side but the area of BIOPEX®  decreased due to resorption in the 
experimental side after 24 weeks. 
On the other hand, although resorption of absorbable plates was not observed at all 
within 24 weeks, osteoblasts were observed under the plate after 4 weeks. In other 
words, this study also proved that the Super FIXSORB®-MX could induce new bone 
formation, as previously reported.  
    In conclusion, this study suggested that the use of an absorbable plate (Super 
FIXSORB®-MX) in combination with BIOPEX® was useful and bothSuper 
FIXSORB®-MX and BIOPEX® could provide adequate bone regeneration and maintain 
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FIGURE 1.  Intra-operative findings.  
(A) Bone defect was made at the nasal region.  
(B) Surgically–created bone defects. (a) Right side, Control side: no material was 
implanted within the defects. (b) Left side, experimental side: BIOPEX® was implanted 
within the defects.  
(C) In each side, Super-FIXSORBⓇ-MX plate (straight, 2 halls) and two screws (2×5 
mm) were fixed across the surgical defect.  
 
FIGURE 2.  The coronal section of the nasal region with implanted materials. *: The 
blue colored area between the screws and under the absorbable plate indicates the area 
to measure new bone and BIOPEX®. **:  This shows the area to measure BMP-2 
stained cells. A; absorbable plate (Super- FIXSORBⓇ-MX), N; nasal membrane, NB; 
new bone, M; mother bone, T; BIOPEX® 
 
FIGURE 3.  Photomicrographs of the control side. (A) 1 week,  (B) 4 weeks, (C) 12 
weeks (D) 24 weeks  (HE staining, original magnification ×40), P: positive stained 
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cell. A; absorbable plate (Super-FIXSORBⓇ-MX), N; nasal membrane, NB; new bone, 
M; mother bone, F; fibrous tissue. 
 
FIGURE 4.  Photomicrographs of the experimental side after 1 week.  (A) HE 
staining, original magnification×20, (B) absorbable plate region, HE staining, original 
magnification×400, (C) nasal membrane region , HE staining, original magnification×
400. A; absorbable plate (Super-FIXSORBⓇ-MX), N; nasal membrane, M; mother bone, 
T; BIOPEX®  Fibrous tissue including cell component was not found between 
absorbable plate and BIOPEX®. 
 
FIGURE 5.  Photomicrographs of the experimental side after 4 week.  (A) HE 
staining, original magnification×20, (B) absorbable plate region, HE staining, original 
magnification× 400,  The gap was observed between the absorbable plate and 
BIOPEX® (C) nasal membrane region , HE staining, original magnification×400. (D) 
nasal membrane region, BMP-2 antibody staining, original magnification×400.  A; 
absorbable plate (Super-FIXSORBⓇ-MX), N; nasal membrane, M; mother bone, T; 
BIOPEX®, S; BMP-2 stained cell.  
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FIGURE 6.  Photomicrographs of the experimental side after 12 week.  (A) HE 
staining, original magnification×20, (B) absorbable plate region, HE staining, original 
magnification×400, The gap was observed between the absorbable plate and BIOPEX® 
(C) nasal membrane region , HE staining, original magnification×400. (D) nasal 
membrane region, BMP-2 antibody staining, original magnification × 400.  A; 
absorbable plate (Super-FIXSORBⓇ-MX), N; nasal membrane, M; mother bone, T; 
BIOPEX®, S; BMP-2 stained cell. 
 
FIGURE7.  Photomicrographs of the experimental side after 24 weeks.  (A) HE 
staining, original magnification×20, (B) absorbable plate region, HE staining, original 
magnification×400, New bone formation was observed in the gap between the 
absorbable plate and BIOPEX® (C) nasal membrane region, HE staining, original 
magnification×400. (D) nasal membrane region, BMP-2 antibody staining, original 
magnification × 400.  A; absorbable plate (Super-FIXSORB Ⓡ -MX), N; nasal 
membrane, M; mother bone, T; BIOPEX®, S; BMP-2 stained cell.     
 
FIGURE 8.  The ratio of bone and BIOPEX®.  Area A; Bone area in the 
experimental side, Area B; Bone area in the control side, Area C; BIOPEX area in the 
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experimental side, Area D (Area A+C); Bone area + BIOPEX® area. * shows significant 
difference at P<0.05. 
 
FIGURE 9.  Number of BMP-2 positive cells. * shows significant difference at 
P<0.05. 
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